v3.20.1

Consolidated companies as of December 31, 2019 | 12 Months Ended
--- | ---
Dec. 31, 2019
Consolidated companies as of December 31, 2019 |
Consolidated companies as of December 31, 2019 | 30. Consolidated companies as of December 31, 2019
|  |  |  | Year ended December 31,
|  |  |  | 2019 |  | 2018 |  | 2017
Name of the subsidiary |  | Country |  | % voting right Galapagos NV (directly or indirectly through subsidiaries) |  | Change in % voting right previous period (2019 vs 2018) |  | % voting right Galapagos NV (directly or indirectly through subsidiaries) |  | % voting right Galapagos NV (directly or indirectly through subsidiaries)
BioFocus DPI AG in liquidation |  | Switzerland |  | 100% |  |  |  | 100% |  | 100%
Galapagos Biopharma Belgium BV |  | Belgium |  | 100% |  | 100% |  |  |  |
Galapagos Biopharma Netherlands B.V. |  | The Netherlands |  | 100% |  | 100% |  |  |  |
Galapagos Biopharma Spain S.L.U |  | Spain |  | 100% |  | 100% |  |  |  |
Galapagos Biopharma Italy S.r.l. |  | Italy |  | 100% |  | 100% |  |  |  |
Galapagos Biopharma Germany GmbH |  | Germany |  | 100% |  | 100% |  |  |  |
Galapagos B.V. |  | The Netherlands |  | 100% |  |  |  | 100% |  | 100%
Galapagos Biotech Ltd. (formerly Inpharmatica Ltd.) |  | United Kingdom |  | 100% |  |  |  | 100% |  | 100%
Galapagos GmbH |  | Switzerland |  | 100% |  |  |  | 100% |  | 100%
Galapagos, Inc. (formerly Biofocus, Inc.) |  | United States |  | 100% |  |  |  | 100% |  | 100%
Galapagos NV |  | Belgium |  | Parent company |  |  |  | Parent company |  | Parent company
Galapagos Real Estate 1 BV |  | Belgium |  | 100% |  |  |  | 100% |  |
Galapagos Real Estate 2 BV |  | Belgium |  | 100% |  |  |  | 100% |  |
Galapagos Real Estate Netherlands B.V. |  | The Netherlands |  | 100% |  | 100% |  |  |  |
Galapagos SASU |  | France |  | 100% |  |  |  | 100% |  | 100%
Fidelta d.o.o. |  | Croatia |  | 100% |  |  |  | 100% |  | 100%
Xenometrix, Inc. in liquidation |  | United States |  | 100% |  |  |  | 100% |  | 100%
In the fourth quarter of 2018 we incorporated two new legal entities in Mechelen, Belgium: Galapagos Real Estate 1 BV and Galapagos Real Estate 2 BV. In 2019 we incorporated the following legal entities: Galapagos Biopharma Belgium BV, Galapagos Biopharma Netherlands B.V., Galapagos Biopharma Spain S.L.U., Galapagos Biopharma Italy S.r.l., Galapagos Biopharma Germany GmbH and Galapagos Real Estate Netherlands B.V. There are no significant restrictions on the group’s ability to access or use assets and settle liabilities of one of the group’s subsidiaries.

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of subsidiaries. [Refer: Subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2019-01-01 -Paragraph 17 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_17_b&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2019-01-01 -Paragraph 16 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_16_b&doctype=Standard -URIDate 2019-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph B4 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration